SILVER SPRING, Md. and
RESEARCH TRIANGLE PARK, N.C.,
April 26, 2021 /PRNewswire/ -- United
Therapeutics Corporation (Nasdaq: UTHR) announced today that it
will report its first quarter 2021 financial results before the
market opens on Wednesday, May 5,
2021.
United Therapeutics will host a teleconference on Wednesday, May 5, 2021, at 9:00 a.m. Eastern Time. The teleconference is
accessible by dialing (866) 209-9943 in the United States, with international callers
dialing +1 (825) 312-2282. A rebroadcast of the teleconference will
be available for one week and can be accessed by dialing (800)
585-8367 in the United States,
with international callers dialing +1 (416) 621-4642, and using
access code: 3044748.
This teleconference is also being webcast and can be accessed
via United Therapeutics' website at
https://ir.unither.com/events-and-presentations.
United Therapeutics: Enabling Inspiration
United
Therapeutics Corporation focuses on the strength of a balanced,
value-creating biotechnology model. We are confident in our future
thanks to our fundamental attributes, namely our obsession with
quality and innovation, the power of our brands, our
entrepreneurial culture, and our bioinformatics leadership. We also
believe that our determination to be responsible citizens – having
a positive impact on patients, the environment, and society – will
sustain our success in the long term.
Through our wholly owned subsidiary, Lung Biotechnology PBC, we
are focused on addressing the acute national shortage of
transplantable lungs and other organs with a variety of
technologies that either delay the need for such organs or expand
the supply. Lung Biotechnology is the first public benefit
corporation subsidiary of a public biotechnology or pharmaceutical
company.
Please visit unither.com to learn more.
Forward-Looking Statements
Statements included in this
press release that are not historical in nature are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include, among others, statements relating to our
ability to create value and sustain our success in the long-term,
as well as our efforts to develop technologies that either delay
the need for transplantable organs or expand the supply of
transplantable organs. These forward-looking statements are subject
to certain risks and uncertainties, such as those described in our
periodic reports filed with the Securities and Exchange Commission,
that could cause actual results to differ materially from
anticipated results. Consequently, such forward-looking statements
are qualified by the cautionary statements, cautionary language,
and risk factors set forth in our periodic reports and documents
filed with the Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K. We claim the protection of
the safe harbor contained in the Private Securities Litigation
Reform Act of 1995 for forward-looking statements. We are providing
this information as of April 26, 2021
and assume no obligation to update or revise the information
contained in this press release whether as a result of new
information, future events or any other reason.
For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: ir@unither.com
View original
content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-first-quarter-2021-financial-results-before-the-market-opens-on-wednesday-may-5-2021-301276377.html
SOURCE United Therapeutics Corporation